Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVMZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monitoring a medical-technology firm that juggles esophageal-cancer diagnostics, implantable sensors and multiple financing vehicles isn’t easy. PAVmed’s filings often bundle FDA milestones, warrant conversions and subsidiary updates into dense exhibits. If you’ve ever searched “PAVmed SEC filings explained simply” or wondered why an 8-K mentions EsoGuard trial data, Stock Titan’s AI-powered summaries turn that tangle into clear, actionable notes within seconds.
Every document—from a PAVmed quarterly earnings report 10-Q filing to a sudden 8-K describing Collect+Protect validation—is captured the moment it hits EDGAR. Our platform tags PAVmed insider trading Form 4 transactions and pushes PAVmed Form 4 insider transactions real-time to your dashboard. Need a deeper dive? The engine links each metric in the PAVmed earnings report filing analysis to prior periods, flags liquidity changes in a PAVmed annual report 10-K simplified view, and even highlights pay packages tucked inside a PAVmed proxy statement executive compensation section.
Whether you’re assessing reimbursement risk, tracking PAVmed executive stock transactions Form 4 before capital raises, or simply understanding PAVmed SEC documents with AI, you’ll find the data in context: segment revenue for Lucid Diagnostics, Veris Health burn rates, and 510(k) updates all mapped to historical trends. No spreadsheets to build—just reliable intelligence on PAVmed 8-K material events explained and updated in real time.
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics, completed an underwritten public offering of 28,750,000 shares of Lucid Diagnostics common stock at $1.00 per share, including full exercise of a 3,750,000-share underwriter option. After underwriting discounts and estimated offering expenses, the transaction is expected to generate approximately $26.9 million in net proceeds. Lucid Diagnostics intends to use the proceeds for working capital and general corporate purposes.
The filing is a straightforward capital raise by a subsidiary rather than PAVmed directly and provides a liquidity infusion for Lucid Diagnostics to support operations or near-term needs. No additional financial results, changes in ownership percentages, or specific allocations of the proceeds were disclosed in the text provided.
PAVmed Inc.'s Schedule 13G shows that Sargent Investment Group, LLC reports beneficial ownership of 1,006,300 common shares, representing 5.79% of the class. The filing identifies Sargent as an investment adviser organized in Maryland and indicates the position is held in the ordinary course of business as a passive holding under the Schedule 13G rules.
The filing discloses that Sargent does not hold sole voting power over the shares while it does report power to dispose of or direct disposition for the full amount. The statement also notes that other persons may have rights to dividends or sale proceeds, implying the economic interests are held on behalf of others rather than reflecting a controlling stake.
PAVmed Inc. furnished a Form 8-K dated August 14, 2025 reporting that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and providing a business update. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states the furnished information shall not be deemed "filed" under the Exchange Act nor incorporated by reference except as expressly stated. The report is signed by Dennis McGrath, President and Chief Financial Officer.
FAQ
What is the current stock price of Pavmed (PAVMZ)?
